News

On-Market Share Buy-Back - Acrobat pdf 685k 17 March 2015 On 18 March 2014, leading health imaging company Pro Medicus (ASX: PME) announced the implementation of an on-market share buy-back for a period of 12 months. The attached Appendix 3F confirms the finalisation of that buy-back. Also attached is an Appendix 3C to announce the commencement of a new on-market share buy-back, permitting the Company to acquire up to 10% of the ordinary shares on issue during the last 12 months. In accordance with the Corporations Act, acquisitions under the on-market buy-back cannot commence until 14 days after notice has been given to ASIC, which is from 1 April 2015.

PME CEO on H1 Results Open Briefing - Acrobat pdf 255k 20 February 2015 Open Briefing interviewed Pro Medicus CEO, Dr Sam Hupert, discussing the latest PME Interim Results.    

Pro Medicus Announces Interim Results - Acrobat pdf 113k 20 February 2015 Key Points: First-half net profit increased to $1.61 million from $0.2 million in previous corresponding period Revenue $8.64 million – 42.5% higher than previous corresponding period Cash reserves $14.6 million at 31st December 2014 Revenue flowing from first of three recent US deals Company remains debt-free Interim dividend of 1 cent per share (unfranked) Leading health imaging company, Pro Medicus Limited [ASX: PME] today announced a first-half after-tax profit of $1.61 million for the six months to the end of December 2014, a significant increase over the previous corresponding period. The result from the underlying operations for the period was a profit of $0.98m compared to an underlying profit of $0.2m from the previous corresponding period. Revenue from ordinary activities was $8.64 million – a 42.5% increase over the previous corresponding period. The Company’s Board has resolved to pay an unfranked interim dividend of 1 cent per share. The Company's cash reserves totalled $14.6 million at the end of the period. Dr Sam Hupert, CEO of Pro Medicus, said he was delighted with the Company’s progress during the past six-month period. “Both revenue and profits have improved substantially and we expect this to continue as we phase in our recent US contract wins, the first of which started to contribute to this half’s result. It was also very pleasing to see ongoing improvements in our Australian operations as we rollout our new Visage RIS platform to both existing and new clients.” In summary, the major US sales were: 22 April 2014 A large US health network agreed to use Pro Medicus’ Visage 7 enterprise imaging platform for primary diagnoses and distribution of medical images. Six-year

PME Signs $5M Deal with Zwanger-Pesiri - Acrobat pdf 115k 12 January 2015 Key Points: Zwanger-Pesiri to use Pro Medicus’ Visage 7 for primary diagnoses and clinical distribution of medical images. Five-year deal, with base value to PME of A$5 million (US$4.1 million). Transaction-based model with potential upside. Further reinforces Visage’s position in the private outpatient (Imaging Centre) market. Leading imaging IT company Pro Medicus Limited [ASX: PME] today announced the signing of an A$5 million (US$4.1 million) five-year contract with Zwanger-Pesiri Radiology (“Zwanger-Pesiri”) – a highly respected radiology group and outpatient imaging provider on New York’s Long Island. The group will use Pro Medicus’ Visage 7 enterprise viewer technology as the core component of its Deconstructed PACS® enterprise imaging strategy enabling the group to provide exceptionally fast, state-of-the-art imaging to their reading radiologists and referring physicians. Zwanger-Pesiri is one of the largest US providers of outpatient imaging services with 18 imaging centers and 58 radiologists, regionally distributed across Long Island. The group is known for acquiring the latest in advanced imaging technology being the first private radiology practice in the US to purchase a PET/MRI (positron emission tomography/magnetic resonance imaging) scanner. This is in addition to significant recent investments in 3D mammography or digital breast tomosynthesis (DBT) and other leading edge technologies. “Based on the continued growth of the Zwanger-Pesiri imaging center network, and our strategic investment in the latest modalities, it was apparent that our legacy PACS could not keep up with our needs,” said Dr Steven L. Mendelsohn, CEO. “We are committed to using the most advanced technology and did an extensive review of the available systems on the market. Once we experienced what Visage 7 offered, using our own studies across our own network,

Pro Medicus and Visage Imaging at RSNA 2014 To all of our guests and global customers, thank you for making RSNA 2014 such a tremendous success for Pro Medicus and Visage Imaging!  We enjoyed spending time with you in our newly enlarged RSNA booth, listening to your challenges, your aspirations and strategies for enterprise imaging for 2015.  As has become a bit of tradition, we’ve crafted our “top five” observations coming out of the industry’s largest, most anticipated trade show of the year.  And if you didn’t attend RSNA, we hope you find the observations insightful: 1.  The Lines Have Been Drawn At RSNA 2014, it’s quite clear that there are two technology camps—you are either a legacy PACS or you aren’t.  The market now sees through PACS vendor ‘marketecture’ of vague jargon and creative massaging of buzzwords to fit their agenda du jour. The terms “enterprise/universal viewer", “VNA", and "enterprise worklist” are not native to PACS and merely a marketing reaction to the concept of deconstructing a PACS.  All of a sudden, systems that were developed as a silo’d PACS (many in fact, developed last century) are now being marketed as VNA, as universal viewers, and enterprise worklists.  The fact is, these systems weren’t designed as modular components, were never intended to be plug-n-play with third-party systems and never will be.   Square peg, round hole. PACS archives pitched as independent VNAs?  PACS diagnostic workstations suddenly promoted as universal?  PACS-driven workflow offered as enterprise capable?  Also, layer after layer of image viewers on top of thick-client PACS, with dated architectures, are far from ideal.  Layers are great when you live in Minnesota to keep you warm and cozy, but in PACS, too many

Results of Annual General Meeting 2014 - Acrobat pdf 129k 21 November 2014 Pro Medicus announced the results of the Annual General Meeting (AGM), on 21 November 2014.   The results may be downloaded via the above link.

Annual General Meeting November 2014 - Acrobat pdf 3,100k 21 November 2014 On 21 November 2014, Pro Medicus held their Annual General Meeting (AGM).  The Chairman's Address, Chairman's Report, and CEO Address to the AGM are available for download via the above link.  

PME Signs $8M Deal with WellSpan Health - Acrobat pdf 117k 20 November 2014 Key Points: WellSpan to use Pro Medicus’ Visage 7 technology for primary diagnoses and clinical distribution of medical images Seven-year deal, with base value to PME of A$8 million (US$7 million) Transaction-based model with potential upside Second large US deal for PME in past seven months Leading e-health company Pro Medicus Limited [ASX: PME] today announced the signing of an A$8 million (US$7 million) seven-year contract with WellSpan Health (“WellSpan”) – a large regional health network in the north-eastern United States. This is the second large US contract Pro Medicus has signed in the past seven months. The contract will see WellSpan use Pro Medicus’ Visage 7 technology as a core component of its new enterprise imaging platform for the next seven years, and possibly longer. WellSpan is a highly regarded, regional not-for-profit health network operating principally in the US states of (south central) Pennsylvania and (northern) Maryland. Impressively, WellSpan operates the region’s only accredited Level 1 Trauma Center and Primary Stroke Center. It spans 93 patient care locations and a network of four hospitals. WellSpan York Hospital, WellSpan Gettysburg Hospital, WellSpan Ephrata Community Hospital and the WellSpan Surgery & Rehabilitation Hospital. WellSpan serves a patient population of more than 650,000 people, has more than 11,000 employees, and is consistently ranked a top 100 US integrated healthcare network. The contract, which is based on an operational (transactional) model, covers a seven-year term with an estimated value to Pro Medicus in excess of A$8 million (US$7 million) over the life of the contract, with potential for further upside. Under the agreement, Visage 7 technology will be used throughout the WellSpan network for primary

PME Signs Large US Health Network - Acrobat pdf 110k 22 April 2014 Key Points: Large US health network to use Pro Medicus’ Visage 7 enterprise imaging platform for primary diagnoses and distribution of medical images Six-year deal, with base value to PME of $A20M Transaction-based model with potential upside Leading e-health company Pro Medicus Limited [ASX: PME] today announced the signing of a contract with a large US health network which will use Pro Medicus’ Visage 7 technology as a core component of its new enterprise imaging platform. Under the agreement, Visage technology will be used for primary diagnosis by radiologists, as well as distribution of diagnostic images to the client’s extensive base of referring physicians via electronic medical records integration. The contract, which is based on an operational (transaction) model, covers a six-year term with a base contract value of $A20M to Pro Medicus with potential for further upside as the use of the technology is expanded throughout the health system. Dr Sam Hupert, Pro Medicus’ CEO, said the deal was the culmination of efforts by our global team spanning Australia, Europe and the USA. “We are extremely pleased that a health system as large and well regarded as this one has recognized the unique benefits of our technology and the value it delivers.”